Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le(Johns Hopkins University), Luis A. Díaz(Memorial Sloan Kettering Cancer Center), Bjarne R. Bartlett(State University of New York), Leslie Cope(Bloomberg (United States)), Robert A. Anders(Johns Hopkins University), Nianqing Xiao(Caris Life Sciences (United States)), Ludmila Danilova(Bloomberg (United States)), Cara Wilt(Sidney Kimmel Comprehensive Cancer Center), Janis M. Taube(Bloomberg (United States)), George A. Fisher(Stanford University), Nickolas Papadopoulos(Johns Hopkins University), Dan Laheru(Johns Hopkins University), Fay Wong(Howard Hughes Medical Institute), Laveet K. Aulakh(Howard Hughes Medical Institute), Kristen K. Ciombor(The Ohio State University), Amanda N. Fader(Johns Hopkins University), Franck Housseau(Centre National de la Recherche Scientifique), Tim F. Greten(National Cancer Institute), Kenneth W. Kinzler(Johns Hopkins University), James R. Eshleman(Johns Hopkins University), Nilofer S. Azad(Johns Hopkins Hospital), Austin G. Duffy(Mater Misericordiae University Hospital), Drew M. Pardoll(Bloomberg (United States)), Bert Vogelstein(Johns Hopkins University), Atif Zaheer(Johns Hopkins University), Todd S. Crocenzi(Providence Portland Medical Center), Richard M. Goldberg(Ontario Institute for Cancer Research), Christian F. Meyer(Sidney Kimmel Comprehensive Cancer Center), Kellie N. Smith(Bloomberg (United States)), David Spetzler(Caris Life Sciences (United States)), Holly Kemberling(Johns Hopkins University), Katherine M. Bever(Sidney Kimmel Comprehensive Cancer Center), Matthias Holdhoff(Johns Hopkins University), Brandon Luber(Johns Hopkins University), Deborah K. Armstrong(Johns Hopkins University), Shibin Zhou(Johns Hopkins University), Hao Wang(University of Electronic Science and Technology of China), James J. Lee(UPMC Hillman Cancer Center), Steve Lu(Memorial Sloan Kettering Cancer Center), Aleksandra Eyring(Johns Hopkins University), Soonmo Peter Kang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ross C. Donehower(Unknown), Agnieszka A. Rucki(Bloomberg (United States)), Andrew K. Joe(Merck & Co., Inc., Rahway, NJ, USA (United States)), Bao H. Lam(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jennifer N. Durham(Sidney Kimmel Comprehensive Cancer Center)
Cited by 6,625
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Cancer Genome Landscapes
|Science|2013|8k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k